These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23059198)

  • 21. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
    Komajda M; Tavazzi L; Swedberg K; Böhm M; Borer JS; Moyne A; Ford I;
    Eur J Heart Fail; 2016 Sep; 18(9):1182-9. PubMed ID: 27210035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
    Gheorghiade M; Orlandi C; Burnett JC; Demets D; Grinfeld L; Maggioni A; Swedberg K; Udelson JE; Zannad F; Zimmer C; Konstam MA
    J Card Fail; 2005 May; 11(4):260-9. PubMed ID: 15880334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
    Mentz RJ; Allen BD; Kwasny MJ; Konstam MA; Udelson JE; Ambrosy AP; Fought AJ; Vaduganathan M; O'Connor CM; Zannad F; Maggioni AP; Swedberg K; Bonow RO; Gheorghiade M
    Eur J Heart Fail; 2013 Jan; 15(1):61-8. PubMed ID: 22968743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M;
    Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
    Vaduganathan M; Goldsmith SR; Senni M; Butler J; Gheorghiade M
    Eur J Heart Fail; 2016 Feb; 18(2):185-91. PubMed ID: 26443242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Mentz RJ; Greene SJ; Ambrosy AP; Vaduganathan M; Subacius HP; Swedberg K; Maggioni AP; Nodari S; Ponikowski P; Anker SD; Butler J; Gheorghiade M
    Circ Heart Fail; 2014 May; 7(3):401-8. PubMed ID: 24737459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Fonarow GC; Zannad F; Maggioni AP; Konstam MA; Subacius HP; Nodari S; Butler J; Gheorghiade M;
    Am J Cardiol; 2013 Dec; 112(11):1763-9. PubMed ID: 24095030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
    Mentz RJ; Schmidt PH; Kwasny MJ; Ambrosy AP; O'Connor CM; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Gheorghiade M
    J Card Fail; 2012 Jul; 18(7):515-23. PubMed ID: 22748484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Subacius HP; Chioncel O; Maggioni AP; Swedberg K; Zannad F; Konstam MA; Senni M; Givertz MM; Butler J; Gheorghiade M;
    Am J Cardiol; 2014 Dec; 114(11):1713-21. PubMed ID: 25312638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
    O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
    Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
    J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
    Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.
    Dauriz M; Targher G; Temporelli PL; Lucci D; Gonzini L; Nicolosi GL; Marchioli R; Tognoni G; Latini R; Cosmi F; Tavazzi L; Maggioni AP;
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28679559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
    Blair JE; Khan S; Konstam MA; Swedberg K; Zannad F; Burnett JC; Grinfeld L; Maggioni AP; Udelson JE; Zimmer CA; Ouyang J; Chen CF; Gheorghiade M;
    Eur Heart J; 2009 Jul; 30(13):1666-73. PubMed ID: 19411662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.
    Chiong JR; Kim S; Lin J; Christian R; Dasta JF
    J Med Econ; 2012; 15(2):276-84. PubMed ID: 22111754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk following hospitalization in stable chronic systolic heart failure.
    Abrahamsson P; Swedberg K; Borer JS; Böhm M; Kober L; Komajda M; Lloyd SM; Metra M; Tavazzi L; Ford I
    Eur J Heart Fail; 2013 Aug; 15(8):885-91. PubMed ID: 23460732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).
    Cook TD; Greene SJ; Kalogeropoulos AP; Fonarow GC; Zea R; Swedberg K; Zannad F; Maggioni AP; Konstam MA; Gheorghiade M; Butler J
    Am J Cardiol; 2016 Feb; 117(4):611-616. PubMed ID: 26742474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.